

Special Issue

Pathogenesis, Diagnosis, and Therapeutics of Infectious Diseases

Message from the Guest Editors

Infectious diseases represent a major threat to the health and wellbeing of humans on a global scale, especially following the COVID pandemic. The Sustainable Development Agenda for 2030 aims to end the epidemics of AIDS, tuberculosis, malaria, and neglected tropical diseases, and to combat hepatitis, water-borne diseases, and other communicable diseases by 2030, which is extremely important. On the other hand, the COVID pandemic sharpened the focus on developing new technologies to prevent diseases and protect the people, and all these achievements should be promoted, explored, and discussed among scientists, in order to increase their benefits for all. Sharing experience and knowledge about the recent developments related to infectious diseases will be beneficial for all scientists and countries to improve the surveillance and control of these diseases in their countries and improve resilience of the health systems. Authors are invited to submit their recent studies on the pathogenesis, diagnostic and therapy for infectious diseases as well as responses of health systems.

Guest Editors

Prof. Dr. Adriana Pistol

Faculty of Medicine, Carol Davila University of Medicine and Pharmacy,
050474 Bucharest, Romania

Dr. Jianbo Yue

Department of Biomedical Sciences, City University of Hong Kong,
Hong Kong, China

Deadline for manuscript submissions

closed (31 March 2024)



Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed



mdpi.com/si/146815

Biomedicines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
biomedicines@mdpi.com

[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)





Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed



[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)



About the Journal

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPUS / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17 days after submission; acceptance to publication is undertaken in 2.9 days (median values for papers published in this journal in the first half of 2025).